# US 2010/0167417 A1 · Long wavelength thiol-reactive fluorophores

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167417 A1
- Document ID: US20100167417A1
- Status: Published application
- Kind: A1
- Application number: 12/489,078
- Filed: 2009-06-22
- Published: 2010-07-01
- Earliest claimed: 2004-05-21
- Assignees: Becton, Dickinson and Company
- Inventors: J. Bruce Pitner; Douglas B. Sherman; K. Joseph Thomas
- Web page: https://patentgrep.com/patent/US20100167417A1

## CPC

- C09B 23/10: The polymethine chain containing an even number of >CH- groups {(styryl dyes C09B23/14, C09B23/14 takes precedence)}
- C07D 207/02: with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C09B 23/105: {two >CH- groups}
- G01N 33/582: {with fluorescent label}
- G01N 33/66: involving blood sugars, e.g. galactose
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm. Biosensors are disclosed having a binding protein and a squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus.

## Claims

### Claim 1

A compound having the formula
A-Y
where A is a benzodioxazole nucleus
and where Y is
where n is an integer of 1 to 6;
A′-CO—R1, where A′ is —R2O— or —R2N(R3)—, where R2 is a C1 to C6 alkyl, R3 is H or CH3, and R1 is CH2Cl, CH2Br, CH2I; or
where m is an integer of 2 to 6.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R2 is a C2 to C4 alkyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R2 is CH2CH2.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2O is —CH2CH2O—.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2N(R3)— is —CH2CH2NH—.

### Claim at position 6

6-13. (canceled)

### Claim 14 (depends on 1)

The compound of claim 1, wherein A is a benzodioxazole nucleus having the formula selected from the group consisting of:
where r is an integer of 1 to 3, R8 and R9 are independently a C1 to C6 alkyl or (CH2)sCO2H, where s is an integer of 2 to 5, Z is S, O, or C(CH3)2, W is H, CH3, SO3H, fused benzene, or fused sulfobenzene,
and where Y is as defined in claim 1.

### Claim 15 (depends on 14)

The compound of claim 14, wherein said compound is

### Claim 16 (depends on 14)

The compound of claim 14, wherein said compound is

### Claim 17 (depends on 1)

The compound of claim 1, wherein A is a benzodioxazole nucleus having the formula selected from the group consisting of:
where r is an integer of 1 to 3, R8 and R9 are independently a C1 to C6 alkyl or (CH2)sCO2H, where s is an integer of 2 to 5, W is H, CH3, SO3H, fused benzene, or fused sulfobenzene,
and where Y is defined as in claim 1.

### Claim 18 (depends on 17)

The compound of claim 17, wherein said compound is

### Claim at position 12

19-22. (canceled)

### Claim 23

A biosensor compound having the formula
A-Y′—B
where A is a fluorophore that exhibits a fluorescence emission and has a benzodioxazole nucleus
where Y′—B is
where n is an integer of 1 to 6,
or where Y′—B is A′-CO—V—B, where A′ is —R2O— or —R2N(R3)—, where R2 is a C1 to C6 alkyl, R3 is H or CH3, and V—B is —CH2—B or
where m is an integer of 2 to 6, and
B is a receptor having a binding affinity for a ligand to be detected, and where said biosensor compound exhibits a detectable change in a fluorescence property as a result of binding of said ligand.

### Claim 24 (depends on 23)

The biosensor compound of claim 23, wherein said receptor is a binding protein.

### Claim 25 (depends on 23)

The biosensor compound of claim 23, wherein B is a periplasmic binding protein.

### Claim 26 (depends on 23)

The biosensor compound of claim 23, wherein said biosensor fluorescence emission is above 575 nm.

### Claim 27 (depends on 23)

The biosensor compound of claim 23, wherein B is a glucose/galactose binding protein (GGBP).

### Claim 28 (depends on 23)

The biosensor compound of claim 23, wherein said binding protein is glucose/galactose binding protein having at least one amino acid substitution and where said at least one amino acid substitution is selected from the group consisting of a cysteine at position 11, a cysteine at position 14, a cysteine at position 19, a cysteine at position 43, a cysteine at position 74, a cysteine at position 107, a cysteine at position 110, a cysteine at position 112, a cysteine at position 113, a cysteine at position 137, a cysteine at position 149, a cysteine at position 213, a cysteine at position 216, a cysteine at position 238, a cysteine at position 287, a cysteine at position 292, a cysteine at position 112 and a serine at position 238, a cysteine at position 149 and a serine at position 238, a cysteine at position 152 and a serine at position 213, a cysteine at position 213 and a cysteine at position 238, a cysteine at position 149 and an arginine at position 213, a cysteine at position 149 and a serine at position 213 and a serine at position 238, and a cysteine at position 149 and an arginine at position 213 and a serine at position 238.

### Claim 29 (depends on 23)

The biosensor compound of claim 23, wherein R2O is —CH2CH2O—.

### Claim 30 (depends on 23)

The biosensor compound of claim 23, wherein R2N(R3) is —CH2CH2NH—.

### Claim 31 (depends on 23)

The biosensor compound of claim 23, wherein said
A-Y′—B
is selected from the group consisting of:
where Y′—B is
where n is an integer of 1 to 6,
or where Y′—B is A′-CO—V—B, where A′ is —R2O— or —R2N(R3)—, where R2 is a C1 to C6 alkyl, R3 is H or CH3, and V—B is —CH2—B or
where m is an integer of 2 to 6, and
B is a receptor having a binding affinity for a ligand to be detected, and where said biosensor compound exhibits a detectable change in a fluorescence property as a result of changes in concentration of said ligand.

### Claim 32 (depends on 23)

The biosensor compound of claim 23, wherein said
A-Y′—B
is selected from the group consisting of
where B is as defined in claim 23.

### Claim 33

A method for detecting analyte comprising:
providing a biosensor compound having at least one mutated binding protein with a fluorophore covalently attached thereto through a thiol group of said binding protein, where said fluorophore exhibits an emission fluorescence of at least 575 nm and has a benzodioxazole nucleus,
contacting said binding protein with an analyte source to bind said analyte to said binding protein; and
subjecting said binding protein to an energy source to excite said fluorophore and detecting a fluorescence property as an indicator of an analyte or analyte concentration in said analyte source.

### Claim 34 (depends on 33)

The method of claim 33, wherein said binding protein is a periplasmic binding protein.

### Claim 35 (depends on 33)

The method of claim 33, wherein said method comprises continuously contacting said binding protein with said analyte source, continuously subjecting said binding protein to said energy source and continuously detecting said fluorescence property.

### Claim 36 (depends on 33)

The method of claim 33, wherein said mutated binding protein undergoes a conformational change as a result of changes in analyte concentration of said analyte source and where said method detects changes in said fluorescence property as a result of changes in said analyte concentration.

### Claim 37 (depends on 33)

The method of claim 33, wherein said mutated binding protein is a glucose/galactose binding protein having at least one amino acid substitution selected from the group consisting of a cysteine at position 11, a cysteine at position 14, a cysteine at position 19, a cysteine at position 43, a cysteine at position 74, a cysteine at position 107, a cysteine at position 110, a cysteine at position 112, a cysteine at position 113, a cysteine at position 137, a cysteine at position 149, a cysteine at position 213, a cysteine at position 216, a cysteine at position 238, a cysteine at position 287, a cysteine at position 292, a cysteine at position 112 and a serine at position 238, a cysteine at position 149 and a serine at position 238, a cysteine at position 152 and a serine at position 213, a cysteine at position 213 and a cysteine at position 238, a cysteine at position 149 and an arginine at position 213, a cysteine at position 149 and a serine at position 213 and a serine at position 238, and a cysteine at position 149 and an arginine at position 213 and a serine at position 238.

### Claim 38 (depends on 33)

The method of claim 33, wherein said biosensor compound has the formula
A-Y′—B
where A has a benzodioxazole nucleus
Y′—B is
where n is an integer of 1 to 6, or Y′—B is A′—CO—V—B, where
A′ is —R2O— or —R2N(R3)— where R2 is a C1 to C6 alkyl, R3 is H or CH3, V—B is —CH2—B or
where m is an integer of 2 to 6 and
B is said periplasmic binding protein.

### Claim 39 (depends on 33)

The method of claim 33, wherein B is a glucose/galactose binding protein or a maltose binding protein.

### Claim 40 (depends on 38)

The method of claim 38, wherein R2O is —CH2CH2—O—.

### Claim 41 (depends on 38)

The method of claim 38, wherein R2N(R3) is —CH2CH2NH—.

### Claim 42 (depends on 38)

The method of claim 38, wherein
A-Y′—B
is selected from the group consisting of
where Y′—B is
where n is an integer of 1 to 6,
or where Y′—B is A′-CO—V—B, where A′ is —R2O— or —R2N(R3)—, where R2 is a C1 to C6 alkyl, R3 is H or CH3, and V—B is CH2—B or
where m is an integer of 2 to 6, and
B is a receptor having a binding affinity for a ligand to be detected, and where said biosensor compound exhibits a detectable change in a fluorescence property as a result of changes in concentration of said ligand.

### Claim 43 (depends on 38)

The method of claim 38, wherein
A-Y′—B
is selected from the group consisting of
where B is as defined in claim 38.
